PCVX Stock Price, Vaxcyte, Inc. Quote, Chart

Market Summary

USD62.46+0.22

Market Closed

0.35%

PCVX Alerts

4 major insider sales recently.

PCVX Stock Price

View Fullscreen

PCVX RSI Chart

PCVX Valuation

Market Cap

6.8B

Price/Earnings (Trailing)

-16.83

Price/Sales (Trailing)

1.4K

Price/Free Cashflow

-21.64

PCVX Price/Sales (Trailing)

PCVX Profitability

Return on Equity

-32.43%

Return on Assets

-28.57%

Free Cashflow Yield

-4.62%

PCVX Fundamentals

PCVX Revenue

Revenue (TTM)

4.8M

Rev. Growth (Yr)

-99.3%

Rev. Growth (Qtr)

-99.6%

PCVX Earnings

Earnings (TTM)

-402.3M

Earnings Growth (Yr)

-131.65%

Earnings Growth (Qtr)

-95.11%

Breaking Down PCVX Revenue

Last 7 days

-0.1%

Last 30 days

-8.2%

Last 90 days

2.7%

Trailing 12 Months

41.6%

How does PCVX drawdown profile look like?

PCVX Financial Health

Current Ratio

7.54

PCVX Investor Care

Shares Dilution (1Y)

20.48%

Diluted EPS (TTM)

-4.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.4M	4.2M	5.7M	4.8M
2022	1.7M	2.1M	1.9M	1.9M
2021	0	2.5M	1.8M	1.9M
2020	797.3K	1.4M	1.9M	2.5M
2019	0	0	0	237.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaxcyte, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	wassil jim	sold	-200,066	66.6885	-3,000	chief operating officer
Apr 01, 2024	eydelman mikhail	acquired	35,690	21.41	1,667	svp, gen counsel & corp sec
Apr 01, 2024	eydelman mikhail	sold	-111,234	66.7271	-1,667	svp, gen counsel & corp sec
Apr 01, 2024	pickering grant	sold	-174,502	66.7055	-2,616	chief executive officer
Mar 25, 2024	pickering grant	sold	-1,003,980	66.9319	-15,000	chief executive officer
Mar 25, 2024	pickering grant	acquired	26,850	1.79	15,000	chief executive officer
Mar 18, 2024	guggenhime andrew	sold	-552,144	69.018	-8,000	president and cfo
Mar 18, 2024	guggenhime andrew	acquired	42,800	5.35	8,000	president and cfo
Mar 15, 2024	wassil jim	sold (taxes)	-103,435	69.7	-1,484	chief operating officer
Mar 15, 2024	wassil jim	acquired	-	-	4,099	chief operating officer

Which funds bought or sold PCVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Legato Capital Management LLC	reduced	-34.33	-218,814	547,095	0.07%
Apr 15, 2024	Ellsworth Advisors, LLC	sold off	-100	-506,168	-	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	93.00	1,161	-%
Apr 10, 2024	Banque Cantonale Vaudoise	added	96.68	43,000	81,000	-%
Apr 09, 2024	Rise Advisors, LLC	new	-	15,643	15,643	0.01%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	478	478	-%
Apr 05, 2024	GAMMA Investing LLC	added	97.78	2,866	6,080	-%
Apr 05, 2024	CWM, LLC	added	89.47	1,000	2,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	25.31	154,507	438,720	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.03	108,478,000	530,809,000	0.01%

Are Funds Buying or Selling PCVX?

Are funds buying PCVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PCVX

No. of Funds

PCVX Alerts

4 major insider sales recently.

Unveiling Vaxcyte, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.99%	9,685,079	SC 13G/A
Feb 13, 2024	janus henderson group plc	7.3%	6,981,376	SC 13G/A
Feb 13, 2024	vanguard group inc	8.88%	8,452,371	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	9.0%	8,575,238	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	8,153,559	SC 13G/A
Feb 10, 2023	tpg gp a, llc	1.5%	1,190,336	SC 13G/A
Feb 10, 2023	carlyle group inc.	2.6%	2,070,724	SC 13G/A
Feb 10, 2023	janus henderson group plc	7.6%	5,974,139	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Vaxcyte, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to Vaxcyte, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Vaxcyte, Inc. News

Latest updates

Vaxcyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-99.6%	7.00	1,640	2,464	654	925	157	690	160	908	299	378	326	787	1,036	329	-
Operating Expenses	74.0%	196,676	113,026	87,147	71,192	86,573	58,577	47,886	39,221	29,846	26,951	23,730	19,453	21,308	21,224	27,596	15,837
S&GA Expenses	12.3%	17,527	15,605	14,456	13,112	11,952	10,898	9,417	7,543	6,772	6,523	6,079	4,792	4,898	3,046	3,281	2,456
R&D Expenses	6.9%	104,150	97,421	72,691	58,080	51,626	47,679	38,469	31,678	23,074	20,428	17,651	14,661	16,410	18,178	24,315	13,381
Interest Expenses	-	-	-	-	-	-	-	2.00	-	-	-	7.00	-	-	-	7.00	7.00
Net Income	-95.1%	-180,801	-92,664	-68,339	-60,462	-78,050	-57,917	-48,532	-38,986	-28,563	-26,615	-23,679	-20,737	-21,018	-20,320	-27,142	-14,621
Net Income Margin	-60.2%	-84.43*	-52.71*	-63.05*	-100.99*	-115.71*	-90.86*	-69.37*	-67.53*	-63.14*	-51.02*	-42.66*	-	-	-	-	-
Free Cashflow	-106.6%	-134,064	-64,887	-60,602	-53,299	-66,368	-39,391	-40,064	-30,622	-52,475	-30,134	-30,888	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-5.9%	1,408	1,496	1,503	1,008	1,006	412	412	403	324	354	358	382	393	404	416	66.00
Current Assets	-15.4%	1,096	1,295	1,310	841	943	370	364	342	256	303	302	325	389	401	413	62.00
Cash Equivalents	-27.1%	397	545	531	380	835	279	239	203	70.00	113	152	200	386	397	410	59.00
Net PPE	596.6%	80.00	11.00	16.00	15.00	10.00	10.00	10.00	10.00	8.00	7.00	6.00	5.00	3.00	3.00	3.00	3.00
Liabilities	79.4%	167	93.00	69.00	63.00	53.00	53.00	45.00	43.00	40.00	48.00	41.00	55.00	47.00	40.00	33.00	12.00
Current Liabilities	69.9%	145	86.00	60.00	53.00	41.00	39.00	30.00	27.00	29.00	47.00	41.00	55.00	47.00	40.00	33.00	11.00
Shareholder's Equity	-11.6%	1,240	1,403	1,433	945	954	359	367	360	284	306	317	327	346	364	383	-
Retained Earnings	-24.3%	-924	-743	-650	-582	-522	-444	-386	-337	-298	-270	-243	-219	-198	-177	-156	-109
Additional Paid-In Capital	0.7%	2,165	2,148	2,087	1,527	1,476	804	754	698	583	576	560	547	544	542	540	3.00
Shares Outstanding	0.3%	95.00	95.00	94.00	81.00	79.00	62.00	61.00	58.00	52.00	52.00	52.00	51.00	-	-	-	-
Float	-	-	-	4,100	-	-	-	1,100	-	-	-	789	-	-	-	950	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-123.8%	-128,810	-57,548	-62,742	-47,690	-65,221	-38,548	-39,126	-27,702	-51,093	-28,415	-28,680	-13,205	-10,768	-13,055	-9,172	-13,633	-14,406	-9,458	-	-
Share Based Compensation	1.0%	13,348	13,220	12,544	9,648	7,009	6,648	5,894	4,099	3,158	2,937	2,769	1,865	1,935	1,838	1,289	372	375	265	-	-
Cashflow From Investing	-162.5%	-13,926	22,280	-333,564	-448,101	-35,952	34,706	26,165	49,666	82.00	-18,469	-20,530	-173,391	-722	21.00	-55.00	-349	-953	-60.00	-	-
Cashflow From Financing	-94.4%	2,735	48,550	546,966	41,562	656,633	44,017	49,878	111,019	8,754	7,599	956	487	555	36.00	264,482	109,797	41,352	368	-	-

PCVX Income Statement

2023-12-31

Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Operating expenses:

Research and development (including related party expenses of $0, $0 and $2,359 in 2023, 2022 and 2021, respectively)

$ 332,341

$ 169,451

$ 78,411

Acquired manufacturing rights (Note 7)

75,000

22,995

0

General and administrative

60,700

39,810

25,259

Total operating expenses

468,041

232,256

103,670

Loss from operations

(468,041)

(232,256)

(103,670)

Other income (expense), net:

Interest expense

0

(2)

(7)

Interest income

62,907

8,356

344

Grant income

4,765

1,931

1,585

Realized gains on marketable securities

0

2

Loss on disposal of fixed assets

0

(44)

0

Foreign currency transaction (losses) gains

(1,897)

(1,470)

1,669

Total other income, net

65,775

8,771

3,593

Net loss

$ (402,266)

$ (223,485)

$ (100,077)

Net loss per share, basic

$ (4.14)

$ (3.44)

$ (1.93)

Net loss per share, diluted

$ (4.14)

$ (3.44)

$ (1.93)

Weighted-average shares outstanding, basic

^[1]

97,157,690

64,877,988

51,922,108

Weighted-average shares outstanding, diluted

^[1]

97,157,690

64,877,988

51,922,108

[1]	Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, “Pre-Funded Warrants.”

PCVX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 397,451	$ 834,657
Short-term investments	682,776	96,719
Prepaid expenses and other current assets	15,727	11,179
Total current assets	1,095,954	942,555
Property and equipment, net	79,626	10,360
Operating lease right-of-use assets	30,997	21,288
Long-term investments	162,675	26,549
Restricted cash	1,103	871
Other assets	37,562	4,555
Total noncurrent assets	311,963	63,623
Total assets	1,407,917	1,006,178
Current liabilities:
Accounts payable	14,587	9,795
Accrued compensation	11,056	1,180
Accrued manufacturing expenses	52,767	8,265
Accrued expenses	59,815	15,375
Operating lease liabilities - current	7,113	5,910
Total current liabilities	145,338	40,525
Operating lease liabilities - long-term	22,111	12,031
Other liabilities	0	9
Total liabilities	167,449	52,565
Commitments and contingencies (Note 7)
Stockholders' Equity
Preferred stock, $0.001 par value - 10,000,000 authorized at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2023 and December 31, 2022; 95,364,831 and 79,470,670 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	98	82
Additional paid-in capital	2,164,583	1,476,018
Accumulated other comprehensive income (loss)	179	(361)
Accumulated deficit	(924,392)	(522,126)
Total stockholders' equity	1,240,468	953,613
Total liabilities and stockholders' equity	$ 1,407,917	$ 1,006,178

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

CEO	Mr. Grant E. Pickering M.B.A.
WEBSITE	https://vaxcyte.com
INDUSTRY	Biotechnology
EMPLOYEES	158

Vaxcyte, Inc. Frequently Asked Questions

What is the ticker symbol for Vaxcyte, Inc.? What does PCVX stand for in stocks?

PCVX is the stock ticker symbol of Vaxcyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxcyte, Inc. (PCVX)?

As of Wed Apr 17 2024, market cap of Vaxcyte, Inc. is 6.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers. The fair value of Vaxcyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxcyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxcyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCVX is over valued or under valued. Whether Vaxcyte, Inc. is cheap or expensive depends on the assumptions which impact Vaxcyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCVX.

What is Vaxcyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, PCVX's PE ratio (Price to Earnings) is -16.83 and Price to Sales (PS) ratio is 1.42 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCVX PE ratio will change depending on the future growth rate expectations of investors.